Lilly, Alkermes release data showing Exubera oral insulin as good as injected

09/13/2005 | Forbes

In response to an FDA advisory panel's concerns about their inhaled insulin drug, Exubera, Eli Lilly and Alkermes disclosed data showing their drug worked as well as the usual injected form of insulin. The firms also said they have begun enrollment for a Phase III trial aimed at assessing the safety and efficacy of the drug.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT